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For many years, we have grown used to the infrequent arrival of
new drugs to the market place. These represent the tip of the
iceberg; many others undergo testing in phase I and II trials and
fail to progress. The slow and steady stream of new drug
development has been replaced by an enormous expansion of
agents and therefore activity of phase I trials. Literally hundreds of
new compounds have been generated over the last few years
through expansion of knowledge of molecular biology and
synthesis of agents to target recently identified cellular pathways
and their receptors. The arrival of a book on Phase I Cancer Trials
is timely.
The key strength and uniqueness of this book is, as its subtitle
describes – a Practical Guide to Phase I Cancer Clinical Trials. The
chapters take the reader in a clear and stepwise manner through
the design, ethical aspects, writing of protocols and conduct of
studies. The layout of the chapters is clear and very suitable for
oncologists or scientists stepping into the world of first-in man
studies. Of particular interest to this group are the chapters on how
to write a protocol and file for regulatory submission. The latter
deals with differences on the two sides of the Atlantic and the
increasingly complex legal and regulatory processes involved in
academic trials. The detailed and methodical approach is a clear
testament to Elizabeth Eisenhauer and her colleagues’ considerable
personal experience in dealing with this complex area.
I particularly liked the table inserted in the chapter on the
preparation of the trial with lists of the Sponsor’s responsibilities.
A similar table on running a trial lists what to do if the unexpected
happens. There is a substantial appendix with practical informa-
tion – web resources and references and a sample protocol,
consent form and other useful documentation. For completeness I
would like to have seen included the NCI Common Terminology
Criteria for Adverse Events v3.0.
Drug development and clinical trials are fundamental to the
practice of medical oncology. Understanding the processes
involved in developing and conducting clinical trials and active
participation in them is an essential component of training and
practice. Phase I clinical studies have hitherto been relatively
straightforward, selecting an active drug based on the maximum
tolerated dose and taking successful candidate agents into phase
II trials. ‘More is better’ has been a paradigm that has only
recently been challenged. This has created some difficulty for
those working in early clinical trials. Maximum tolerated dose now
is only one of a number of possible end points that include
biological markers and surrogate measures of response. The
clearly written chapter from Chris Twelves on the principles of
pharmacokinetics and pharmacodynamics addresses this impor-
tant area well, using up to date examples. Pharmacodynamics has
become a more complex subject, now not only focusing on the
effect of a drug on normal tissue, for example, bone marrow, but
also its action on tumour tissue targets or other surrogate markers.
Added to this are the growing number of studies that use positron
emission tomography and magnetic resonance imaging. The latter,
using dynamic contrast enhanced MRI, has been used extensively
to evaluate vascular targeting agents. I would have welcomed even
more detail on these topics, particularly tissue-based assays and
surrogate end points.
No book on clinical trials is complete without a chapter
on statistics, and Marc Buyse has dealt with this well. Classical
design methods, their modification and newer approaches are
explained clearly in a language that non-statisticians can easily
understand.
This book is the first of its kind and should have a place on a
library shelf. It is a very readable account of a complex area of
oncology research. It is a handbook that I expect will soon be
found lying on the desk of most trial units conducting early phase
studies. It is likely to be referred to frequently, particularly as it is
easy to dip into specific chapters to find the required information.
It provides an excellent introduction and guide to the world of
phase I cancer clinical trials.
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